Trial ChiCTR2200057758
Publication Zhang Y, EClinicalMedicine, 2022
Primary outcome on the report: The geometric mean titres (GMTs) of neutralising antibodies against the wild-type, delta and omicron variants of live SARS-CoV-2 at day 0 (pre-vaccination), 7, 14, and 28 after boosting vaccination ; the occurrence of adverse events within 14 days after the booster vaccination.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.